posted
im recommending go long if you are not already out, ive heard they have come out with new innovative solutions, read up on some of their current announcements, we might be looking at this thing headed up again, im gonna watch it closer for the next week and decide what to do
IP: Logged |
posted
IT moves about as fast as a stock can move with buyers, I imagine if this breast cancer treatment goes through this stock will be a monster and a half.
-------------------- Love 'em or Leave 'em either way I already did it.
IP: Logged |
posted
Some great news Staph infection are a growing concern in the medical community this drug could revolutionize the industry and safe many lives.
Symbollon Receives Regulatory Guidance for Development of Products in Upper Respiratory Tract Aug 2, 2006 9:53:00 AM FRAMINGHAM, MA -- (MARKET WIRE) -- 08/02/06 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is pleased to announce it has received regulatory guidance concerning the appropriate preclinical steps necessary to initiate human clinical trials for its new drug, Nasodine(TM). After discussions with the FDA, the company is planning to conduct a 30-day repeat dose animal study prior to filing an investigational new drug (IND) application in 2007. Nasodine is a proprietary formulation designed to eliminate drug-resistant Staphylococcus aureus (Staph) in the nasal cavity. Symbollon believes the market opportunity for Nasodine could easily be in the hundreds of millions per year.
Part of Symbollon's business strategy is to develop a family of safe, broad-spectrum antimicrobial products based on its proprietary free molecular iodine platform technology that will eradicate pathogens without genetic drug resistance. With the increasing threat of the spread of multi-drug resistant "superbugs," Symbollon anticipates that its new line of products will help eradicate these disease-causing pathogens. This new line of products represents a safe alternative to existing antibiotics which are suffering from ever decreasing effectiveness due to genetic drug resistance. The company is considering antimicrobial product opportunities for the upper respiratory tract, oral cavity and skin.
"We are pleased to have received guidance from the FDA regarding the appropriate preclinical activities necessary to initiate human clinical studies on Nasodine," commented Paul Desjourdy, the President and CEO of Symbollon Pharmaceuticals, Inc. "We believe the healthcare system is in need of a product that can be used to prevent Staph infections caused by contaminated nasal cavities. In America alone, every year about 2 million people acquire bacterial infections while in the hospital and approximately 90,000 of them die as a result, according to the Centers for Disease Control and Prevention in Atlanta. Staph is one of the key pathogens causing those infections, and subsequent deaths. Nasodine has the unique advantage that it can be used prophylacticly without fear of genetic drug resistance. In an ideal world, all at-risk patient populations and health care workers would utilize Nasodine to help eliminate the chance of infections. Some of the at-risk patient populations include HIV, surgical and hemodialysis patients."
About Symbollon Pharmaceuticals, Inc.
Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon is conducting a Phase III clinical trial evaluating IoGen as a potential treatment for moderate to severe periodic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). FBD is a condition that affects approximately 20 to 33 million women in the U.S., and there are approximately 7 to 13 million women suffering from clinical periodic mastalgia. The Company believes IoGen also may be useful in treating and/or preventing endometriosis, ovarian cysts, and premenopausal breast cancer. Symbollon is also in preclinical development of antimicrobial products based on the same molecular iodine technology, and intends to investigate the potential effectiveness of its technology in applications such as dermatology, oral care, upper respiratory tract conditions, urinary tract infection and wound care. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.
Forward-Looking Statement: This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) future clinical trial results will support the use of IoGen for the treatment of fibrocystic breast disease, (ii) the clinical data acquired from Mimetix Inc. will be acceptable exposure data for IoGen, (iii) Symbollon will be able to obtain the resources necessary to continue as a going concern, (iv) IoGen will successfully complete the regulatory approval process, (v) competitive products will receive regulatory approval, (vi) the Company's ability to enter into new arrangements with corporate partners, (vii) the Company's partner for IoGen will be able to meet its financial obligation to pay for the IoGen clinical development and (viii) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.
CONTACT: Paul C. Desjourdy President and CEO Symbollon Pharmaceuticals, Inc. (508) 620-7676, x202 www.symbollon.com
posted
Yes it could be a monster in the near future. I really like the staph infection drug I have been reading articles in the newspaper on how that is becoming rampant in hospitals school and jails, not to mention you local gym.
-------------------- Love 'em or Leave 'em either way I already did it.
IP: Logged |
posted
Wow only ik traded and the MM's are eager to move up the price, I can only imagine what would happen on a heavily traded day the float is so low this one moves lightning fast.
-------------------- Love 'em or Leave 'em either way I already did it.
IP: Logged |
posted
Symbollon Provides Update on IoGen Phase III Pain Study Aug 9, 2006 8:45:00 AM FRAMINGHAM, MA -- (MARKET WIRE) -- 08/09/06 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) announced that it anticipates closing the enrollment of its IoGen(TM) Phase III pivotal pain study by year-end. The ongoing IoGen study has over 25 active sites across the United States. Symbollon is planning to conduct a comprehensive advertising campaign during the remainder of 2006 to assist these sites in recruiting subjects for the study by yearend. With enrollment completed by yearend, Symbollon expects to announce the study results in the summer of 2007.
The multi-center Phase III pivotal clinical trial is evaluating the clinical effectiveness of IoGen in women with moderate to severe periodic breast pain associated with fibrocystic breast disease (FBD). Currently, there are 25 randomized subjects in the study and an additional 26 subjects enrolled in the screening process. Symbollon is planning to randomize up to approximately 130 women in the study.
Randomized subjects will receive one 6.0 mg tablet of IoGen or placebo daily for six months. The primary objective of the study is to evaluate the effectiveness of IoGen by comparing subjects in the treatment and placebo groups that experience a clinically meaningful reduction in breast pain and tenderness. Nodularity (lumpiness caused by excess breast tissue) will be evaluated by physicians and used as a secondary efficacy endpoint.
"We are determined to complete the enrollment of this critical study by the end of 2006," stated Paul Desjourdy, the President and CEO of Symbollon Pharmaceuticals, Inc. "With our increase financial funding we believe that we finally have adequate resources to complete the patient enrollment in this study. This timetable will allow us to announce the data in the summer of 2007."
About Symbollon Pharmaceuticals, Inc.:
Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon is conducting a Phase III clinical trial evaluating IoGen as a potential treatment for moderate to severe periodic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). FBD is a condition that affects approximately 20 to 33 million women in the U.S., and there are approximately 7 to 13 million women suffering from clinical periodic mastalgia. The Company believes IoGen also may be useful in treating and/or preventing endometriosis, ovarian cysts, and premenopausal breast cancer. Symbollon is also in preclinical development of antimicrobial products based on the same molecular iodine technology, and intends to investigate the potential effectiveness of its technology in applications such as dermatology, oral care, upper respiratory tract conditions, urinary tract infection and wound care. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.
Forward-Looking Statement: This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) future clinical trial results will support the use of IoGen for the treatment of fibrocystic breast disease, (ii) the clinical data acquired from Mimetix Inc. will be acceptable exposure data for IoGen, (iii) Symbollon will be able to obtain the resources necessary to continue as a going concern, (iv) IoGen will successfully complete the regulatory approval process, (v) competitive products will receive regulatory approval, (vi) the Company's ability to enter into new arrangements with corporate partners, (vii) the Company's partner for IoGen will be able to meet its financial obligation to pay for the IoGen clinical development and (viii) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.
CONTACT: Paul C. Desjourdy President and CEO Symbollon Pharmaceuticals, Inc. (508) 620-7676, x202 www.symbollon.com
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
